Clinical trial
Celecoxib to Treat Macular Degeneration in Patients Receiving Photodynamic…
NCT00043680 · National Eye Institute (NEI), NIH · Completed
Key facts
| NCT number | NCT00043680 |
|---|---|
| Title | Celecoxib to Treat Macular Degeneration in Patients Receiving Photodynamic Therapy |
| Official title | Multi-Center Randomized Phase I/II Trial to Study the Effects of Cyclooxygenase-2 Inhibition on the Response to Photodynamic Therapy in Patients With Age-Related Macular Degeneration |
| Lead sponsor | National Eye Institute (NEI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Macular Degeneration |
| Intervention type | Drug |
| Interventions | Celecoxib |
| Enrollment | 60 |
| Start date | Aug 1, 2002 |
| Completion | Jan 1, 2005 |
| First posted | Aug 12, 2002 |
| Last update posted | Mar 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: